These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 28660280)
1. Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma. Barel F; Guibourg B; Lambros L; Le Flahec G; Marcorelles P; Uguen A Acta Derm Venereol; 2018 Jan; 98(1):44-49. PubMed ID: 28660280 [TBL] [Abstract][Full Text] [Related]
2. Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice. Uguen A; Guéguen P; Legoupil D; Bouvier S; Costa S; Duigou S; Lemasson G; Ledé F; Sassolas B; Talagas M; Férec C; Le Maréchal C; De Braekeleer M; Marcorelles P Hum Pathol; 2015 Nov; 46(11):1582-91. PubMed ID: 26297254 [TBL] [Abstract][Full Text] [Related]
3. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas. Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954 [TBL] [Abstract][Full Text] [Related]
4. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331 [TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay. Vallée A; Denis-Musquer M; Herbreteau G; Théoleyre S; Bossard C; Denis MG PLoS One; 2019; 14(8):e0221123. PubMed ID: 31415669 [TBL] [Abstract][Full Text] [Related]
6. Feasibility and performance of the Idylla™ NRAS/BRAF cartridge mutation assay on thyroid liquid-based fine-needle aspiration. Hamadou M; Lopez J; Benzerdjeb N; Cugnet-Anceau C; Schnoering G; Besançon J; Mezrag S; Lapras V; Denier ML; Descotes F; Decaussin-Petrucci M Diagn Cytopathol; 2021 Dec; 49(12):1265-1271. PubMed ID: 34698448 [TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232 [TBL] [Abstract][Full Text] [Related]
8. Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma. Melchior L; Grauslund M; Bellosillo B; Montagut C; Torres E; Moragón E; Micalessi I; Frans J; Noten V; Bourgain C; Vriesema R; van der Geize R; Cokelaere K; Vercooren N; Crul K; Rüdiger T; Buchmüller D; Reijans M; Jans C Exp Mol Pathol; 2015 Dec; 99(3):485-91. PubMed ID: 26407762 [TBL] [Abstract][Full Text] [Related]
9. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428 [TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma. Knol AC; Pandolfino MC; Vallée A; Nguyen F; Lella V; Khammari A; Denis M; Puaux AL; Dréno B Exp Dermatol; 2015 Jan; 24(1):70-3. PubMed ID: 25363723 [TBL] [Abstract][Full Text] [Related]
11. BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi. Francis JH; Grossniklaus HE; Habib LA; Marr B; Abramson DH; Busam KJ Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):117-121. PubMed ID: 29332123 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma. Massi D; Simi L; Sensi E; Baroni G; Xue G; Scatena C; Caldarella A; Pinzani P; Fontanini G; Carobbio A; Urso C; Mandalà M Mod Pathol; 2015 Apr; 28(4):487-97. PubMed ID: 25341653 [TBL] [Abstract][Full Text] [Related]
13. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples. Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967 [TBL] [Abstract][Full Text] [Related]
14. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation]. Lázár V Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354 [TBL] [Abstract][Full Text] [Related]
15. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma. Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471 [TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma. Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140 [TBL] [Abstract][Full Text] [Related]
17. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2. Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173 [TBL] [Abstract][Full Text] [Related]
18. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026 [TBL] [Abstract][Full Text] [Related]
19. Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases. Pellegrini C; Cardelli L; Padova M; Nardo LD; Ciciarelli V; Rocco T; Cipolloni G; Clementi M; Cortellini A; Ventura A; Leocata P; Fargnoli MC Acta Derm Venereol; 2020 Jan; 100(1):adv00040. PubMed ID: 31774543 [TBL] [Abstract][Full Text] [Related]
20. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases. Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]